@article{52723af711074af2b9815c33ce0660aa,
title = "Tau Positron Emission Tomography Binding Is Not Elevated in HIV-Infected Individuals",
abstract = "Regional standardized uptake value ratios (SUVRs) for tau positron emission tomography (PET) were compared among 19 cognitively normal human immunodeficiency virus (HIV)-negative control individuals, 20 HIV-negative patients with symptomatic Alzheimer disease, 15 cognitively normal HIV-positive individuals, and 17 cognitively impaired HIV-positive individuals. Among the HIV-positive participants, the correlation between tau PET SUVRs and both HIV loads and CD4+ T-cell counts (recent and nadir). Tau PET SUVRs were similar for HIV-positive individuals and HIV-negative control individuals. Individuals with symptomatic Alzheimer disease had elevated tau PET SUVRs. Tau PET SUVRs did not correlate with impairment or clinical markers in HIV-positive participants. Older HIV-positive individuals are not at increased risk of tau-mediated neurodegeneration.",
keywords = "Alzheimer's disease, HIV dementia, positron emission tomography",
author = "Cooley, {Sarah A.} and Strain, {Jeremy F.} and Helen Beaumont and Boerwinkle, {Anna H.} and John Doyle and Morris, {John C.} and Benzinger, {Tammie L.} and Ances, {Beau M.}",
note = "Funding Information: This work was supported by the National Institutes of Health - National Institute of Nursing Research (grants R01NR012907, R01NR012657, and R01NR014449 to B.M.A), National Institutes of Health - National Institute on Aging (grants P01AG00391, P01AG026276, and P01AG005681 to J.C.M.); Barnes-Jewish Hospital; the National Institutes of Health - National Center for Advancing Translational Sciences (grant UL1 TR000448); the Hope Center for Neurological Disorders; the Paula and Rodger O. Riney Fund; the Daniel J Brennan MD Fund; Fred Simmons and Olga Mohan; and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly; provision of the precursor for AV-1451, chemistry support for the production of this compound, and doses of the compound). Funding Information: Financial support. This work was supported by the National Institutes of Health - National Institute of Nursing Research (grants R01NR012907, R01NR012657, and R01NR014449 to B.M.A), National Institutes of Health - National Institute on Aging (grants P01AG00391, P01AG026276, and P01AG005681 to J.C.M.); Barnes-Jewish Hospital; the National Institutes of Health - National Center for Advancing Translational Sciences (grant UL1 TR000448); the Hope Center for Neurological Disorders; the Paula and Rodger O. Riney Fund; the Daniel J Brennan MD Fund; Fred Simmons and Olga Mohan; and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly; provision of the precursor for AV-1451, chemistry support for the production of this compound, and doses of the compound). Publisher Copyright: {\textcopyright} 2018 The Author(s) 2018.",
year = "2019",
month = jun,
day = "5",
doi = "10.1093/infdis/jiy663",
language = "English",
volume = "220",
pages = "68--72",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
number = "1",
}